Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Liposome (VIM) vs VIT in Pediatric Relapsed/Refractory Soft Tissue Sarcoma
NCT06514313Phase 2Recruiting
- Start
- Jul 2024
- Primary completion
- Aug 2026
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in soft tissue sarcoma (STS) (2 arms). Primary endpoint: Objective Response Rate. Started Jul 2024; status: recruiting.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06514313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06514313.